Meet Oxford Biotech CEO/Founders!

Event Information

Share this event

Date and Time

Location

Location

BioEscalator

The Innovation Building The Old Road Campus

Roosevelt Drive, Headington

Oxford

OX3 7FZ

United Kingdom

View Map

Event description

Description

The Oxford University Biotech Society invites you to join us on 14th November at the Bioescalator Building for a fantastic opportunity to network with some of the rising biotechs companies in the Oxford ecosystem. The event is hosted by The Oxford BioEscalator: a hub for new and developing life science innovations!

The evening will start with short presentations from each company, followed by an open networking event. This will be an incredible opportunity to interact with some of the best minds and leaders in Oxford who are driving innovation in biotechnology and healthcare!

Get a chance to hear from and network with CEOs, Founders and representatives from the following companies:

Theolytics

  • Charlotte Casebourne – CEO
  • Working closely with the academic founders, Charlotte is leading Theolytics to discover and develop potent, targeted oncolytic viruses for the treatment of a pipeline of cancer indications through the directed evolution of the viruses. The company has raised £2.5M from Venture funds and is gearing up for a Series A fundraise to develop their technology into the clinic.

PepGen

  • Caroline Godfrey – CEO
  • As a post-doc in the Founder’s Laboratory, Caroline has help develop the technology which underlies Pepgen both inside the University setting and as CEO. The company has raised £2.5M of venture capital and secured a further £1.6M in Government Grants. They are developing new ways to deliver therapeutics by using peptides to penetrate the cell membrane.

MacrophOx

  • Phil Jakeman – Chief Technology Officer
  • MacrophOx is a cell-therapy company developing programmable macrophages which can specifically deliver anti-cancer agents in situ within the tumour microenvironment. Phil completed his DPhil in Oncology and Cancer Biology and continued his research as a Post-doc, he was instrumental in raising the £3.5M to get MacrophOx started and leading the founding team.

Nucleome

  • Danuta Jeziorska – CEO
  • Nucleome Therapeutics spun out of the WIMM in August 2019 with £5.2M investment aiming to unlock the non-coding part of the genome in order to deliver life changing treatments. During her post-doc, Danuta contributed to the platform technology that underpins Nucleome and recognised the commercial value of the work. She developed the business case, lead the fundraising and is now building the company as the CEO.

MiroBio

  • Chris Paluch – Head of Discovery Research
  • Miro has raised £27M from UK and US Biotech investors to advance the work of Chris’s DPhil research which investigated antibodies that can activate modulatory immune receptors. Chris has now joined the company and is leading a research team to broaden this platform and drive these antibodies to the clinic.

MOA

  • Maria Gravato-Nobre – Principal Scientist
  • The team at MoA are developing the next generation of sustainable herbicide chemistries with new modes of action from both natural and synthetic sources. Originally trained as a plant pathologist, and with industrial experience at Zeneca Agrochemicals, Maria had a 19 year career as an academic at Oxford University before joining MoA to apply her expertise in high-throughput screening.

TAPS

  • Ollie Waterhouse – CEO-to-be of TAPS Tech
  • Currently in final stages of Spin-out from the Ludwig centre, TAPS is a new diagnostics company based on a revolutionary epigenetic sequencing technology. Ollie has been leading the company creation as an Entrepreneur-in-Residence at Oxford Sciences Innovation.

Check out our next event on biotech VCs: https://www.eventbrite.co.uk/e/78902352059


Share with friends

Date and Time

Location

BioEscalator

The Innovation Building The Old Road Campus

Roosevelt Drive, Headington

Oxford

OX3 7FZ

United Kingdom

View Map

Save This Event

Event Saved